Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $55,152.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total value of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $55,152.50.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $18.10 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The business has a fifty day simple moving average of $17.20 and a two-hundred day simple moving average of $14.59.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in ELVN. AJOVista LLC bought a new position in Enliven Therapeutics during the 4th quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth $66,000. Exchange Traded Concepts LLC increased its holdings in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics in the 3rd quarter worth about $157,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Mizuho initiated coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.